Written Articles Search for key words or topics here to access our blog archives Dan Sfera 9/20/21 Dan Sfera 9/20/21 NIH will spending nearly $470 million to study long-term effects of COVID Read More Dan Sfera 9/20/21 Dan Sfera 9/20/21 FDA supports third dose for older and high-risk populations Read More Dan Sfera 9/2/21 Dan Sfera 9/2/21 Analysts upgrade forecast for immunooncology company Read More Dan Sfera 9/2/21 Dan Sfera 9/2/21 Two top FDA vaccine regulators are leaving Read More Dan Sfera 9/2/21 Dan Sfera 9/2/21 FDA finalizes intended use rule Read More Dan Sfera 8/29/21 Dan Sfera 8/29/21 Synthetic Biology Hype? Zymergen rallies after Cathie Wood recommendation Read More Dan Sfera 8/29/21 Dan Sfera 8/29/21 Jazz Pharmaceuticals drug gets approval Read More Dan Sfera 8/29/21 Dan Sfera 8/29/21 Lilly forms neuroscience unit Read More Dan Sfera 8/29/21 Dan Sfera 8/29/21 Personal genomics firm becomes holding company via merger Read More Dan Sfera 8/27/21 Dan Sfera 8/27/21 Vaccine becomes first to move beyond emergency approval Read More Dan Sfera 8/24/21 Dan Sfera 8/24/21 Making Sense of Senseonics Read More Dan Sfera 8/16/21 Dan Sfera 8/16/21 Regeneron-Sanofi lung cancer drug study ends positively Read More Dan Sfera 8/16/21 Dan Sfera 8/16/21 Centessa merges 10 privately held biotechs under one umbrella Read More Dan Sfera 8/16/21 Dan Sfera 8/16/21 Analysts upgrading estimates for pharma stock Read More Dan Sfera 8/11/21 Dan Sfera 8/11/21 Company focuses on treating mental health and neurological disorders Read More Dan Sfera 8/10/21 Dan Sfera 8/10/21 Sarepta adds experimental gene therapy to its pipeline Read More Dan Sfera 8/9/21 Dan Sfera 8/9/21 Drug gets FDA approval plus expansion Read More Dan Sfera 8/9/21 Dan Sfera 8/9/21 Drug candidate holds promise for treating breathing-related symptoms caused by COVID Read More Dan Sfera 8/3/21 Dan Sfera 8/3/21 Salarius lead candidate is in nine U.S. trial sites Read More Dan Sfera 8/2/21 Dan Sfera 8/2/21 Lilly pays $1B for Protomer Read More Newer Posts Older Posts
Dan Sfera 9/20/21 Dan Sfera 9/20/21 NIH will spending nearly $470 million to study long-term effects of COVID Read More
Dan Sfera 9/20/21 Dan Sfera 9/20/21 FDA supports third dose for older and high-risk populations Read More
Dan Sfera 8/29/21 Dan Sfera 8/29/21 Synthetic Biology Hype? Zymergen rallies after Cathie Wood recommendation Read More
Dan Sfera 8/29/21 Dan Sfera 8/29/21 Personal genomics firm becomes holding company via merger Read More
Dan Sfera 8/27/21 Dan Sfera 8/27/21 Vaccine becomes first to move beyond emergency approval Read More
Dan Sfera 8/16/21 Dan Sfera 8/16/21 Regeneron-Sanofi lung cancer drug study ends positively Read More
Dan Sfera 8/16/21 Dan Sfera 8/16/21 Centessa merges 10 privately held biotechs under one umbrella Read More
Dan Sfera 8/11/21 Dan Sfera 8/11/21 Company focuses on treating mental health and neurological disorders Read More
Dan Sfera 8/9/21 Dan Sfera 8/9/21 Drug candidate holds promise for treating breathing-related symptoms caused by COVID Read More
